Yes, Azstarys is a stimulant. The FDA classifies it as a central nervous system (CNS) stimulant, and it carries a Schedule II controlled substance designation, the same category as other methylphenidate-based ADHD medications. It was approved in 2021 for treating ADHD in people aged 6 and older.
How Azstarys Works
Azstarys contains two components that work together. About 30% of the capsule is an immediate-release form of dexmethylphenidate, the same active ingredient found in Focalin. The other 70% is a prodrug called serdexmethylphenidate, which the body gradually converts into dexmethylphenidate over time. This two-part design provides a quick onset followed by extended coverage throughout the day.
Once active in the brain, dexmethylphenidate blocks the transporters that normally recycle dopamine and norepinephrine back into nerve cells. This allows those chemical messengers to remain active longer in the spaces between neurons, which improves focus, impulse control, and attention. That mechanism is the defining feature of stimulant medications for ADHD, and it’s the same basic approach used by Ritalin, Concerta, and other methylphenidate products.
What Makes It Different From Other Stimulants
The prodrug component is the main distinction. Serdexmethylphenidate is pharmacologically inactive on its own. It only becomes a stimulant after enzymes in the body break it down into dexmethylphenidate. This conversion happens gradually, which smooths out the drug’s effects and creates a longer duration of action compared to taking dexmethylphenidate alone.
This prodrug design also lowers the potential for misuse. In human abuse potential studies, participants who took serdexmethylphenidate reported significantly less “drug liking” than those who took equivalent amounts of standard dexmethylphenidate. On a 100-point scale measuring how much participants enjoyed the drug’s effects, serdexmethylphenidate scored around 63 compared to about 82 for standard dexmethylphenidate. The difference held whether the drug was taken orally or by other routes. Despite this reduced abuse potential, the DEA still classifies Azstarys as Schedule II because its active metabolite is identical to other methylphenidate stimulants.
Available Doses
Azstarys comes in three capsule strengths, each listing the prodrug amount first and the immediate-release amount second:
- 26.1 mg / 5.2 mg (lowest dose)
- 39.2 mg / 7.8 mg (middle dose)
- 52.3 mg / 10.4 mg (highest dose)
The capsules can be swallowed whole or opened and sprinkled onto applesauce for children or adults who have difficulty swallowing pills.
Common Side Effects
Because Azstarys is a stimulant, its side effect profile looks similar to other methylphenidate medications. In long-term clinical trials, the most frequently reported issues were decreased appetite (17.6%), upper respiratory tract infections (8%), weight loss (6.7%), and irritability (5.5%). In a separate study, insomnia and mood changes each affected about 9 to 13% of participants depending on the phase of the trial.
Appetite suppression and weight loss were among the most noticeable effects overall. Roughly a quarter to a third of participants across studies experienced decreased appetite or lost weight. About 18% of participants reported stimulation effects, which can include feeling jittery, wired, or overly alert. A small number of patients (around 2%) developed repetitive behaviors like skin picking, nail biting, or hair pulling. Visual hallucinations were rare, reported in about 1% of patients.
Who Azstarys Is Approved For
The FDA approved Azstarys for treating ADHD in children (ages 6 and up), adolescents, and adults. It is not approved for children under 6. Like all Schedule II stimulants, it requires a new prescription each time (no automatic refills), and prescribers typically start at the lowest dose before adjusting upward based on how well symptoms are controlled and how the side effects are tolerated.